Biosens

bSens.INR

PT/INR reagent strip test

bSens.INR is in preparation for the Anvisa registration process. It is not yet on sale.

Point-of-care strip test, performed next to the patient, that uses graphene to measure prothrombin time, expressed as the PT/INR value (International Normalized Ratio).

  • Result: the measured INR value, shown on the bSens One portable analyzer.
  • Intended use: self-testing, in preparation for Anvisa registration.

Names you may hear for the same test: coagulation test, PT/INR, prothrombin time.

Hands with a drop of blood on a fingertip, beside the blue analyzer resting on a knee, with the strip seated.

How it works

Three steps between the drop and the result.

bSens.INR measures clotting time from a single drop of blood, on the bSens One portable analyzer.

Illustrative animation. The value on the screen is an example (DEMO).
  1. Prepare the strip and the sample.

    The bSens.INR strip goes into the bSens One analyzer, which gets ready to measure. One drop of blood goes on the sample area, at the tip of the strip.

  2. Measure clotting time.

    The drop reacts with the chemistry on the strip, and the printed electrode turns the reaction into a signal. The analyzer measures that signal and calculates INR.

  3. Read the INR value.

    The analyzer shows the measured INR value. Its interpretation depends on each person's clinical context and is made by the healthcare professional.

From the laboratory to the point of care

Two routes to the PT/INR test.

An illustrative comparison of the steps of the PT/INR test in a traditional laboratory and with a point-of-care test.

Traditional laboratoryPoint-of-care test01Consultation02Testrequest03Laboratoryvisit04Venousbloodcollection05Sampletransport06Sampleanalysis07Waiting forthe result08Follow-upconsultation01Consultation02Test with one drop ofblood03INR value on theanalyzer04Result passed to thehealthcareprofessional05Follow-up by thehealthcareprofessionalINRDEMO2.4
Illustration. The value on screen is a demo value, not a patient result.
  • Traditional laboratory

    • Consultation and test request.
    • Trip to the laboratory and venous blood collection.
    • Sample transport and analysis.
    • Waiting for the result.
    • Another consultation to review the result.
  • Point-of-care test

    • Consultation and recommendation of point-of-care monitoring.
    • Test with one drop of blood.
    • INR value shown on the analyzer.
    • Result passed to the healthcare professional.
    • Follow-up by the healthcare professional.

Conceptual comparison. The intended use of bSens.INR is self-testing, in preparation for Anvisa registration. Interpreting the result depends on each person's clinical context and is made by the healthcare professional.

The system

One analyzer, one strip, one cloud.

The three parts are designed to work as a single system.

Scientific context

What the studies say.

Data from scientific papers and books. They describe the condition, the field and the technology, not bSens products.

  • 62.6%

    At three public anticoagulation clinics in Belo Horizonte (2014 to 2015), 801 people taking warfarin spent on average 62.6% of the time within their INR therapeutic range. An international meta-analysis of atrial fibrillation studies published from 1990 to 2013 found 61%. 1,2

  • 28 trials

    A 2016 Cochrane review pooled 28 randomized trials with 8,950 people on oral anticoagulation. Those who tested their own INR at home had fewer thromboembolic events than with standard monitoring (moderate-quality evidence); major bleeding and overall mortality did not decrease. The authors note that self-testing is not feasible for everyone and requires identifying and educating suitable patients. The results hold for the conditions of these trials, and how the INR is monitored is decided by the healthcare professional with each person. 3,4

  • 148 people

    In a retrospective study at a single hospital in China, 148 people with a mechanical heart valve taking warfarin chose between INR monitoring at the hospital and self-testing with a portable monitor, with remote guidance from their doctors through an app. Over 12 months, 68.9% of the 74 who self-tested and 39.2% of the 74 at the hospital had at least 60% of their INR tests in the target range. The measure counts tests, not time, and self-testing called for more frequent tests. The finding holds for the conditions of this study, and how the INR is monitored is decided by the healthcare professional with each person. 5

  • Common scale

    The INR (international normalized ratio) expresses the prothrombin time on a common scale and is calculated with the ISI, a calibration index referenced to a WHO international standard. The target range depends on the clinical indication and is set for each person by the healthcare professional. The Brazilian valve disease guideline says the INR is usually checked once a month. 6,7,8,9

  • Warfarin

    Under the 2025 Brazilian atrial fibrillation guideline, direct oral anticoagulants are preferred, except for people with a mechanical heart valve or moderate to severe mitral stenosis. In these cases a vitamin K antagonist such as warfarin remains indicated, based on trials in which there were more events with direct anticoagulants. The same guideline calls for an individualized, shared decision: the anticoagulant and any change of treatment are decided by the healthcare professional with each person. 8,10,11,12

References

  1. 1.Viana CC, Praxedes MFDS, Abreu MHNG, et al. Quality of Oral Anticoagulation Control with Warfarin According to Sex: A Cross-Sectional Study. Int J Environ Res Public Health. 2025;22:65. doi:10.3390/ijerph22010065
  2. 2.Mearns ES, White CM, Kohn CG, et al. Quality of vitamin K antagonist control and outcomes in atrial fibrillation patients: a meta-analysis and meta-regression. Thromb J. 2014;12:14. doi:10.1186/1477-9560-12-14
  3. 3.Heneghan CJ, Garcia-Alamino JM, Spencer EA, et al. Self-monitoring and self-management of oral anticoagulation. Cochrane Database Syst Rev. 2016;7:CD003839. doi:10.1002/14651858.CD003839.pub3
  4. 4.Heneghan C, Ward A, Perera R; Self-Monitoring Trialist Collaboration. Self-monitoring of oral anticoagulation: systematic review and meta-analysis of individual patient data. Lancet. 2012;379:322-334. doi:10.1016/S0140-6736(11)61294-4
  5. 5.Huang L, Ouyang C, Ye X, Ren M, Da Q, Han Z. Anticoagulation monitoring using point-of-care testing combined with mobile remote management in postoperative cardiac valve replacement patients receiving warfarin therapy: A single-center cross-sectional study. Medicine (Baltimore). 2026;105:e47395. doi:10.1097/MD.0000000000047395
  6. 6.Ageno W, Gallus AS, Wittkowsky A, Crowther M, Hylek EM, Palareti G. Oral anticoagulant therapy. Chest. 2012;141(2 Suppl):e44S-e88S. doi:10.1378/chest.11-2292
  7. 7.Dorgalaleh A, Favaloro EJ, Bahraini M, Rad F. Standardization of Prothrombin Time/International Normalized Ratio (PT/INR). Int J Lab Hematol. 2021;43:21-28. doi:10.1111/ijlh.13349
  8. 8.Cintra FD, Pisani CF, Rezende AGDS, et al. Diretriz Brasileira de Fibrilação Atrial - 2025. Arq Bras Cardiol. 2025;122:e20250618. doi:10.36660/abc.20250618
  9. 9.Tarasoutchi F, Montera MW, Ramos AIO, et al. Atualização das Diretrizes Brasileiras de Valvopatias - 2020. Arq Bras Cardiol. 2020;115:720-775. doi:10.36660/abc.20201047
  10. 10.Eikelboom JW, Connolly SJ, Brueckmann M, et al. Dabigatran versus warfarin in patients with mechanical heart valves. N Engl J Med. 2013;369:1206-1214. doi:10.1056/NEJMoa1300615
  11. 11.Wang TY, Svensson LG, Wen J, et al. Apixaban or Warfarin in Patients with an On-X Mechanical Aortic Valve. NEJM Evid. 2023;2:EVIDoa2300067. doi:10.1056/EVIDoa2300067
  12. 12.Connolly SJ, Karthikeyan G, Ntsekhe M, et al. Rivaroxaban in Rheumatic Heart Disease-Associated Atrial Fibrillation. N Engl J Med. 2022;387:978-988. doi:10.1056/NEJMoa2209051

Frequently asked questions

Is it a final diagnosis?
No. bSens.INR measures and shows the INR value. Interpretation and the clinical decision belong to the healthcare professional.
Do I need internet?
The analyzer is designed to measure without internet and to sync with bSens Cloud, which is in development, when there is a network.
Is the data stored?
bSens Cloud, in development, is designed to keep each result in a history. Privacy and access to data are still being defined, and we will say so before any use.
How is an INR value interpreted?
INR is a value related to blood clotting. It is interpreted by the healthcare professional, in the context of each person's clinical situation.
What are the analyzer and the strip called technically?
The bSens One portable analyzer is an in vitro diagnostic instrument. In Biosens technical dossiers it also appears as an electronic strip-reading device. For the Anvisa registration process, the technical names in preparation are "Instrumento autoteste para parâmetros de coagulação" for the analyzer and "Autoteste para parâmetros de coagulação" for the strip (in English, self-test instrument for coagulation parameters and self-test for coagulation parameters). They are classification names. On this site we say analyzer and strip. bSens.INR is in preparation for Anvisa registration.

Technical documentation

Documents to download.

Contact

Results at the Point of Care

Get in touch to learn about the bSens system.

Please do not send health information by e-mail. Biosens does not interpret test results or guide treatment.

E-mail

contact@biosens.tech

Address

Av. Theodomiro Porto da Fonseca 3101, Building 3, Room 1, 93022-715, São Leopoldo, RS, Brazil